Polyganics Opens New State-of-the-Art Facility to Drive Growth
Groningen, The Netherlands, 20 April 2021 – Polyganics, a medical technology company developing, manufacturing and commercializing bioresorbable medical devices, today announces its move to a state-of-the art, purpose-built facility on the Zernike Campus, Groningen. The new building will house Polyganics’ research laboratories, manufacturing and packaging facilities, and its offices.
The expansion is essential to accommodate Polyganics’ growing workforce and enable the Company to respond to the increasing demand for its commercial and pipeline products. This includes its own portfolios in PNR (Peripheral Nerve Repair), and Neurosurgery, with LIQOSEAL® gaining commercial traction in Europe, as well as the Stryker-owned NASOPORE® portfolio for ENT (Ear, Nose and Throat) surgery. In the near future, it will also include Polyganics’ new Liver and Pancreas sealant patch, ACTISEAL®, which is currently in clinical trials with first patients treated in Q3 2020.
Polyganics is committed to quality, safety, and sustainability in the development, manufacturing and commercialization of its medical devices, and the Company is determined to operate responsibly to improve environmental sustainability. These values have guided the design and construction of its new facility. Numerous measures have been taken to reduce and optimise energy use, minimize the use of water and enhance safety. For example, more than 600 solar panels have been installed, providing a renewable, clean energy source.
Rudy Mareel, CEO of Polyganics, said: We are happy to be moving into our new facility on schedule, just one year after we broke ground. The new building provides increased manufacturing capacity and space for up to 140 employees, to enable us to meet growing demand. Our lab facilities will be doubled in size, and our manufacturing facilities tripled. We are also delighted to be remaining in Groningen, with our established network of local partners and access to a high-quality talent pool. We look forward to joining the vibrant Zernike Campus, with the further collaborative opportunities this will afford.”
Jan Disbergen, COO of Polyganics added: “On behalf of the Company, I would like to thank the partners that have supported the development of our new facility and helped kickstart the next phase in Polyganics’ evolution. Particular thanks go to the City and the Province of Groningen which awarded us a RIG subsidy. The new building has further increased our focus on the environment and the health and safety of our employees. I would also like to extend my personal thanks to the construction, installation and equipment companies that have played an integral role in this journey.”
Edward van der Meer, Director of Campus Groningen, remarked: “We warmly welcome Polyganics to Campus Groningen, known as Northern Netherland’s Capital of innovation. Polyganics encompasses the collaborative spirit that resides here, where entrepreneurs, researchers and clinicians unite to pursue groundbreaking projects that have a tangible social and economic impact locally and worldwide. With a history of excellence in polymers, Groningen is a fitting home for industry leader, Polyganics and we are confident the Company will bring tremendous value to the campus.”
– ENDS –
For more information please contact:
Paul Roos, Chief Financial Officer
Marleen Schoonen, Director Corporate Communication & Corporate Affairs
T: +31 50 588 65 88
E: email@example.com | firstname.lastname@example.org
Melanie Toyne-Sewell / Dr Katie Duffell
T: +44 (0)20 7457 2020
Notes to editors
Polyganics is a medical technology company with multiple versatile polymer platforms. The company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.
Polyganics’ portfolio comprises of products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. The portfolio includes marketed products in the fields of Peripheral Nerve Repair (PNR) and Neurosurgery: VIVOSORB®, for minimizing unwanted tissue adhesions after surgery; NEUROLAC®, for supporting PNR following hand surgery; NEUROCAP®, for the management of symptomatic neuromas; and LIQOSEAL®, a dura sealant patch for the effective control of cerebrospinal fluid leakage. Products in development include ACTISEAL®, a Liver and Pancreas Sealant Patch in the field of General Surgery.
In 2014, Polyganics sold its Ear, Nose & Throat (ENT) surgery business unit (the NASOPORE® product family including HEMOPORE®, SINUPORE® and OTOPORE® and NASOPORE-FD®) to Stryker, one of the world’s leading medical technology companies. Polyganics continues to manufacture the NASOPORE® product range for Stryker.
Polyganics is a privately held company based in Groningen, The Netherlands. The Company is ISO 13485-certified and its products have received clearance from the US FDA, CE-approval, and approval from the CFDA and other international authorities. Polyganics’ polymer platform technologies are protected by a broad portfolio of patents.
For more information, visit: www.polyganics.com, or follow us on LinkedIn: Polyganics BV